IRIDEX Corporation (IRIX)

Currency in USD
0.990
0.000(0.00%)
Closed·
0.9900.000(0.00%)
·
IRIX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.9901.040
52 wk Range
0.7901.648
Key Statistics
Prev. Close
0.99
Open
1.02
Day's Range
0.99-1.04
52 wk Range
0.79-1.648
Volume
69.45K
Average Volume (3m)
84.42K
1-Year Change
-0.9108%
Book Value / Share
-0.06
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IRIX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.750
Upside
+177.78%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

IRIDEX Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

IRIDEX Corporation Earnings Call Summary for Q4/2025

  • Q4 revenue rose 16% YoY to $14.7M, beating estimates of $13.7M; EPS of -$0.01 surpassed forecast of -$0.02 by 50%
  • Net loss narrowed to $0.2M from $0.8M YoY; operating expenses cut 10% while achieving first positive adjusted EBITDA
  • Cyclo G6 glaucoma platform and PASCAL retina systems drove growth; Q4 generated positive cash flow for first time
  • 2026 operating expenses projected at $19.0-$19.5M; transition to contract manufacturers expected to improve gross margins over two years
  • Stock unchanged at $1.325 post-earnings despite beats; faces risks from tariffs, supply chain issues, and Asia-Pacific headwinds
Last Updated: 26/03/2026, 21:44
Read Full Transcript

Compare IRIX to Peers and Sector

Metrics to compare
IRIX
Peers
Sector
Relationship
P/E Ratio
−3.8x−5.0x−0.4x
PEG Ratio
−0.070.010.00
Price/Book
−15.8x1.0x2.6x
Price / LTM Sales
0.3x1.0x3.1x
Upside (Analyst Target)
177.8%65.2%58.2%
Fair Value Upside
Unlock26.1%8.5%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 2.750
(+177.78% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Alliance Global Partners
Buy3.00+203.03%-New Coverage05/02/2026

Earnings

Latest Release
26/03/2026
EPS / Forecast
-0.01 / -0.02
Revenue / Forecast
14.7M / 13.7M
EPS Revisions
Last 90 days

IRIDEX (IRIX) Income Statement & Profits

People Also Watch

3.09
DXST
-13.20%
1.07
YYGH
+3.88%
1.050
ELUT
-1.87%
0.41
MDCX
-9.64%

FAQ

What Is the IRIDEX (IRIX) Share Price Today?

The IRIDEX stock price today is 0.990 USD.

What Stock Exchange Does IRIDEX (IRIX) Trade On?

IRIDEX is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for IRIDEX?

The stock symbol (also called a 'ticker') for IRIDEX is "IRIX."

What Is the Current IRIDEX Market Cap?

As of today, IRIDEX market cap is 17.020M USD.

What Is IRIDEX's (IRIX) Earnings Per Share (TTM)?

The IRIDEX EPS is currently -0.262 (Trailing Twelve Months).

When Is the Next IRIDEX Earnings Date?

IRIDEX's next earnings report will be released on 07/05/2026.

Is IRIX a Buy or Sell From a Technical Analyst Perspective?

Based on today's IRIDEX moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has IRIDEX Stock Split?

IRIDEX has split 0 times. (See the IRIX stock split history page for full effective split date and price information.)

How Many Employees Does IRIDEX Have?

IRIDEX has 93 employees.

What is the current trading status of IRIDEX (IRIX)?

As of 30/03/2026, IRIDEX (IRIX) is trading at a price of 0.990 USD, with a previous close of 0.990 USD. The stock has fluctuated within a day range of 0.990 USD to 1.040 USD, while its 52-week range spans from 0.790 USD to 1.648 USD.

What Is IRIDEX (IRIX) Price Target According to Analysts?

The average 12-month price target for IRIDEX is 2.750 USD, with a high estimate of 2.75 USD and a low estimate of 2.75 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +177.78% Upside potential.

What Is the IRIX Premarket Price?

IRIX's last pre-market stock price is 1.070 USD. The pre-market share volume is 260.000, and the stock has decreased by 0.080, or 8.080%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.